SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras steep post-IPO selloff is dominating discussion, with traders citing successive share unlocks and insider selling, a TD Cowen price-target cut, and concerns about OpenAI customer concentration and the companys ability to scale. Sentiment is largely bearish, though some investors view the decline as oversold and are averaging down.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves selloff amid weakness in AI-infrastructure stocks has put its heavy debt burden, financing costs and insider selling at the center of the debate; a Goldman Sachs upgrade and reported ARK buying have not eased the concern for many traders. Bears warn of dilution or default, while bulls point to contracted AI-compute demand and see buying opportunities, leaving the stocks support levels in sharp focus.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is caught in a semiconductor selloff as traders question the returns and financing behind AI infrastructure spending, with CEO Hock Tans warning that some AI investing resembles gambling adding to concerns. Bears see his comments and AI-credit risks as reasons for continued weakness, while bulls argue demand and Broadcoms fundamentals remain intact and view the decline as a buying opportunity.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

CIFRs steep selloff is being tied to its convertible-note financing and debt exchange, which traders criticize for dilution and poor timing amid concerns about leverage and management execution. Bears fear continued pressure, while bulls argue that its AI/HPC data-center contracts support the longer-term case and view the decline as potentially overdone.

Silicon Motion Technology Corp. engages in the development, manufacture, and supply of semiconductor products for the electronics market. The firm’s products include Flash Controllers, Storage Solutions, and others. It offers embedded and expandable storage, radio frequency integrated circuits, and embedded graphics. The company was founded by Wallace C. Kou in November 1995 and is headquartered in Hong Kong.

Silicon Motion Technology Corp - ADR

Silicon Motion Technology Corp.

SIMO is drawing attention for its growth in AI and data-center storage, particularly boot-drive shipments and MonTitan enterprise SSD controllers, alongside strong results and an upbeat outlook. Many traders see room for further growth, while others point to sharp share-price swings, technical weakness and dilution concerns tied to convertible notes.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealths quarterly earnings beat and raised full-year outlook, alongside improved medical-cost trends, are driving attention. Bulls view the results as evidence of a turnaround and welcome the rebound, while skeptics question whether the improvement will last and point to the stocks volatile reaction despite the strong report.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention after a sharp selloff across AI-infrastructure stocks, fueled by concerns about neocloud financing, debt and whether heavy AI spending will generate sufficient returns. Traders are split on whether the rebound from oversold levels signals a recovery or a temporary bounce, with some arguing Nebius is better positioned than more debt-heavy peers.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers recent climb toward a 52-week high and a key round-number resistance level is driving discussion, with traders highlighting bullish chart momentum and a defensive rotation into pharma. Others question whether the move can hold, pointing to resistance and the absence of a single clear near-term catalyst.

Aventus Network

AVT is drawing attention as traders watch a volatile, thinly traded rebound for a breakout, focusing on trading volume and resistance levels. Aventus Clouds decentralized-compute and enterprise-appchain updates provide a bullish project narrative, but traders remain divided over whether momentum can persist amid low liquidity and selling pressure.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to record lows is being linked by traders to concerns about Trumps declining approval and the approaching midterms, alongside doubts about Truth Socials engagement and the companys business fundamentals. Discussion is heavily bearish, though some traders see the decline as a buying opportunity or argue that political headlines alone do not determine the companys value.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stryker Enters Soft-Tissue Robotics With $400 Million CMR Deal

SYK's $400 million investment in CMR Surgical marks its entry into soft-tissue robotics, expanding its surgical portfolio with Versius technology.

AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results

ABBV's neuroscience franchise targets nearly 16% revenue growth in Q3, with established drugs and newer Parkinson's therapies driving expansion.

Johnson & Johnson announces new data showing TREMFYA (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula

Johnson & Johnson announces new data showing TREMFYA (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula Johnson & Johnson announces new data showing TREMFYA (guselkumab) is the only IL-23 to deliver durable fistula remission...

JNJ Investors with $100,000 in Losses Have Opportunity to Join Johnson & Johnson Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Johnson & Johnson (Johnson & Johnson or the Company) (NYSE: JNJ) for violations of the securities laws. INVESTIGATION DETAILS: The investigation...

Johnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy.

Key PointsPharmaceutical outfit Johnson & Johnson recently reported solid overall Q3 numbers with one alarming red flag...

Forget AI Stocks: Buy Med-Tech Stock ISRG Now for 40% Upside 

Intuitive Surgical stock earns a Zacks Rank #2 (Buy) and looks poised for a potential technical breakout as it overtakes vital long-term levels heading into its Q3 earnings release on October 20.

Johnson & Johnson: 3 Key Takeaways for Long-Term Investors

Key PointsOperational sales grew 6% in the third quarter of 2026...

3 Companies Raising Guidance This Earnings Season

Raised guidance is always a welcome development for investors, reflecting improving business trends and management confidence in the outlook. 

XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?

Xenon pauses enrollment in late-stage depression trials after unexpected side effects, while its epilepsy pipeline offers growth potential.

Johnson & Johnson Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Johnson & Johnson (JNJ)

Johnson & Johnson Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Johnson & Johnson (JNJ) Johnson & Johnson Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Johnson & Johnson (JNJ)PR NewswireNEW YORK, Oct. 14, 2026China pricing and...

Johnson & Johnson raised 2026 estimated reported sales guidance to $101B$101.4B, with midpoint $101.2B, and adjusted EPS guidance to $11.05$11.15, midpoint $11.10, or 7.4% and 2.9% at midpoint.

Johnson & Johnsons adjusted EPS and adjusted net earnings declined; STELARA, SIMPONI/SIMPONI ARIA, and REMICADE partially offset Innovative Medicine growth; reported net earnings were $210M and EPS reflected a one-time talc litigation charge.

Johnson & Johnson raised 2026 sales and adjusted EPS guidance; OTTAVA received U.S. FDA market authorization and IMAAVY approval; Innovative Medicine operational sales grew 7.9% with named products among its growth drivers.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

SLS, IBRX Rise Premarket: Funds Raise Their Bets As J&J Stays ‘On The Lookout’ For Deals

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Gamma Investing increased its Sellas stake by 293%, while Courier Capital doubled its ImmunityBio holding to about $1.06 million.</li><li>Everhart reported a $2.96 million Sellas position, while Hennion &amp; Walsh held $3.67 million in ImmunityBio.</li><li>J&amp;J’s Inlexzo generated over $90 million in quarterly sales, providing a competitive benchmark for ImmunityBio.</li></ul>Shares of Sellas Life Sciences (SLS) and ImmunityBio (IBRX) edged higher premarket on Wednesday as investors weighed fresh ownership disclosures alongside Johnson &amp; Johnson’s plans to strengthen its cancer-drug business through strategic deals.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> gained about 0.8% in premarket trading, while&nbsp;<a href="https://stocktwits.com/symbol/IBRX">IBRX</a> rose 0.3%.&nbsp;<h2 class="st-heading-2">Fresh Filings Reveal Bigger Bets On SLS And IBRX</h2>Recent ownership disclosures showed several investors increasing their positions in both companies for the quarter ended Sept. 30. In Sellas, Everhart Financial Group reported 240,213 shares valued at about $2.96 million. Independent Financial Group increased its holding by 3% to 24,000 shares worth $295,440.Gamma Investing raised its SLS stake by 293% to 2,186 shares. Financial Designs moved in the opposite direction, cutting its position by 17.75% to 19,186 shares valued at $236,180.In ImmunityBio, Courier Capital doubled its stake to 112,000 shares worth $1.06 million, adding 56,000 shares. Hennion &amp; Walsh Asset Management increased its holding by 1.45% to 409,749 shares valued at about $3.67 million. B. Riley Wealth Advisors reported an unchanged IBRX stake of 113,000 shares worth $1.07 million.<h2 class="st-heading-2">J&amp;J Outlines Deal Strategy As It Expands Cancer Business&nbsp;</h2>J&amp;J CFO Joe Wolk said that the company is interested in assets that could complement its business. “We always are on the lookout for strategic drivers that could complement our business that makes sense to be in our hands versus where the asset would currently reside, but also creates value for the risk we are bearing on behalf of shareholders,” Wolk said during the call.J&amp;J has already expanded its cancer pipeline through its $1 billion cash acquisition of Firefly Bio, completed in July. The deal added tech designed to deliver protein-degrading treatments directly to cancer cells, including those driven by KRAS mutations.CEO Joaquin Duato outlined the company’s broader goal: “Our ambition is to become the number one oncology company by 2030, with sales projected to exceed $50 billion,” he said. J&amp;J ended the quarter with $17 billion in cash and marketable securities against about $45 billion in debt. It generated over $6 billion in quarterly free cash flow and maintained its full-year forecast of $21 billion.Wolk nevertheless clarified that J&amp;J’s forecast for double-digit growth by the end of the decade rests on internal investments rather than future acquisitions. “It does not assume any inorganic additions at this moment in time,” he said.The call also gave a competitive update for ImmunityBio investors. Tom Cavanaugh, J&amp;J’s worldwide chairman of Innovative Medicine, said bladder-cancer treatment Inlexzo generated more than $90 million in third-quarter sales, with new patient inserts rising 45% from the previous quarter. The firm said it sees a sales opportunity exceeding $5 billion for the broader platform as it pursues additional patient populations.<h2 class="st-heading-2">SLS And IBRX Catalyst Watch</h2>Sellas is awaiting the final analysis of its Phase 3 Regal trial, which tests cancer-vaccine candidate Galinpepimut-S in acute myeloid leukemia (AML) patients in second complete remission. The analysis requires 80 deaths, up from the last reported 78, and will be followed by data verification before results are released.&nbsp;Meanwhile, initial Phase 2 results for SLS009, also called Tambiciclib, in newly diagnosed AML patients are expected in the fourth quarter.&nbsp;ImmunityBio is focused on expanding Anktiva’s reach. The immunotherapy is approved or authorized across 34 countries, and second-quarter net product revenue rose 92% year-over-year to $50.7 million. A Food and Drug Administration (FDA) decision is expected by Jan. 6, 2027, on expanding Anktiva plus Bacillus Calmette-Guérin (BCG) to patients with BCG-unresponsive bladder cancer involving papillary tumors without carcinoma in situ.<h2 class="st-heading-2">How Do Retail Traders Feel About SLS And IBRX?</h2>On Stocktwits, SLS sentiment was 'bearish' amid 'high' message volume, while IBRX sentiment was 'neutral' amid 'low' message volume.&nbsp;“Guys it’s a sign. JnJ locked in!” one SLS user&nbsp;<a href="https://stocktwits.com/Biobanker/message/666423145">said</a>. Another&nbsp;<a href="https://stocktwits.com/7is7/message/666437906">asked</a>, “When would the buyout be?”<stembedurl>https://stocktwits.com/7is7/message/666437906</stembedurl>On ImmunityBio’s feed, discussion of J&amp;J focused on rival Inlexzo. One user&nbsp;<a href="https://stocktwits.com/bike_it_59/message/666391216">questioned</a> whether J&amp;J had disclosed the drug’s sales and cited analyst estimates around $70 million.&nbsp;<stembedurl>https://stocktwits.com/bike_it_59/message/666391216</stembedurl>So far this year, IBRX has surged 395%, while SLS has gained 229%.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spacex-worth-50-trillion-10-years-ron-baron-elon-thinks-im-way-low/cZxfiwQRBpg">SpaceX Could Be Worth $50 Trillion In 10 Years, Says Ron Baron: ‘Elon Thinks I’m Way Low’&nbsp;</a>

In this photo illustration, a Johnson & Johnson logo seen displayed on a monitor. (Photo Illustration by Valera Golovniov/SOPA Images/LightRocket via Getty Images)

J&J is open to strategic acquisitions and targets more than $50 billion in oncology sales by 2030.

ImmunityBio Inc

SELLAS Life Sciences Group Inc

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$253.79
Prev Close	$255.56
Open	$254.43
Dividend Yield	2.48%
50-Day Moving Average	$265.12
Beta	-0.01
Avg. Volume	6.3M
PE Ratio	38.50

52-Week High	$281.07
52-Week Low	$184.66
Market Capitalization	$615.87B
EPS (Annual)	$11.03
Price to Book	7.19
Revenue Per Employee	$668,877.84

Feed

News

Sentiment

Earnings

NewFutures

Fundamentals

Info

JNJ Fundamentals